12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FG-4592: Phase IIb started

Last October, FibroGen began a Phase IIb trial to compare thrice-weekly FG-4592 vs. Epogen epoetin alfa for 19 weeks in CKD patients on hemodialysis. Astellas' decision to advance...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >